San Francisco, CA, United States of America

Weijun Feng


 

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 2005

Loading Chart...
Loading Chart...
1 patent (USPTO):

Title: Weijun Feng: Innovator in Nuclear Receptor Modulation

Introduction

Weijun Feng is a notable inventor based in San Francisco, CA. He has made significant contributions to the field of nuclear receptor modulation, particularly through his innovative patent.

Latest Patents

Weijun Feng holds a patent titled "Methods for modulating nuclear receptor coactivator binding." This invention relates to methods and agonist/antagonist compounds for modulating nuclear receptor coactivator binding. The patent includes a method for identifying residues that comprise a coactivator binding site for a nuclear receptor of interest. Additionally, it provides a method for identifying agonists and/or antagonists that bind to a coactivator binding site of a nuclear receptor. The invention exemplifies the identification and manipulation of the coactivator binding site of the thyroid receptor (TR) and includes compounds that bind to these sites. The methods can also be applied to other nuclear receptors, including RAR, RXR, PPAR, VDR, ER, GR, PR, MR, and AR. Weijun Feng has 1 patent to his name.

Career Highlights

Throughout his career, Weijun Feng has worked with esteemed organizations such as the University of California and Thornhill Therapeutics, Inc. His work has significantly advanced the understanding of nuclear receptor interactions and their modulation.

Collaborations

Weijun Feng has collaborated with notable colleagues, including John D Baxter and Beatrice Darimont, who have contributed to his research endeavors.

Conclusion

Weijun Feng's innovative work in nuclear receptor modulation has paved the way for advancements in therapeutic applications. His contributions continue to influence the field and inspire future research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…